PMS2 and neoplasm: These patterns potentially reflect the later discovery of the ‘newer’ MMR genes MSH6 and PMS2, changes in MMR tumour ‘screening’ practices from MSI to IHC, difficulties establishing assays for PMS2 due to the presence of pseudogenes, and more recently increased capacity of Next-generation Sequencing (NGS) to deliver panel testing.